This company listing is no longer active
Clover Biopharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Clover Biopharmaceuticals has a total shareholder equity of CN¥28.6M and total debt of CN¥410.0M, which brings its debt-to-equity ratio to 1435.8%. Its total assets and total liabilities are CN¥3.1B and CN¥3.1B respectively.
Key information
1,435.8%
Debt to equity ratio
CN¥409.95m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥1.30b |
| Equity | CN¥28.55m |
| Total liabilities | CN¥3.05b |
| Total assets | CN¥3.08b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 2197's short term assets (CN¥2.8B) exceed its short term liabilities (CN¥2.4B).
Long Term Liabilities: 2197's short term assets (CN¥2.8B) exceed its long term liabilities (CN¥683.2M).
Debt to Equity History and Analysis
Debt Level: 2197 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 2197's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2197 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 2197 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 66.7% each year